Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889589 | 1.00 | ADRB3 (0.44) | ADRB3HPGDADRB2ADRB1NR1I2 | |
| SCHEMBL4772779 | 1.00 | ADRB3 (0.44) | ADRB3HPGDADRB2ADRB1NR1I2 | |
| Trifluoroacetic Acid SCHEMBL4778942 | 0.96 | ADRB3 (0.41) | ADRB3HPGDADRB2ADRB1NR1I2 | |
| SCHEMBL4897148 | 0.91 | ADRB3 (0.43) | ADRB3HPGDADRB2ADRB1 | |
| SCHEMBL4893736 | 0.91 | ADRB3 (0.43) | ADRB3HPGDADRB2ADRB1 | |
| SCHEMBL4897137 | 0.91 | ADRB3 (0.43) | ADRB3HPGDADRB2ADRB1 | |
| SCHEMBL4892557 | 0.90 | ADRB3 (0.43) | ADRB3HPGDADRB2ADRB1NR1I2 | |
| SCHEMBL4773347 | 0.89 | ADRB3 (0.42) | ADRB3HPGDADRB2ADRB1NR1I2 | |
| SCHEMBL4772787 | 0.89 | ADRB3 (0.42) | ADRB3HPGDADRB2ADRB1NR1I2 | |
| Trifluoroacetic Acid SCHEMBL4894121 | 0.88 | ADRB3 (0.42) | ADRB3HPGDADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1945304-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007048843-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885HPGD 1587/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.